Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma

Can toripalimab-based chemoradiotherapy omit concurrent cisplatin while maintaining survival and improving safety in locoregionally advanced nasopharyngeal carcinoma (NPC)?In this phase 3 randomized clinical trial including 532 patients with locoregionally advanced NPC, those patients receiving toripalimab combined with induction chemotherapy and radiotherapy without concurrent cisplatin had significantly noninferior 3-year failure-free survival (88.3% vs 87.6%) and lower incidence of all-grade vomiting (26.2% vs 59.8%) than the standard therapy group, in which concurrent cisplatin was retained.The toripalimab-based concurrent cisplatin–free strategy offers a promising therapeutic approach that demonstrated both high efficacy and low toxicity in patients with locoregionally advanced NPC.

Corresponding Authors: Jun Ma, MD (majun2@mail.sysu.edu.cn) and Ying Sun, MD (sunying@sysucc.org.cn), Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong 510000, PR China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.